Recombinant HCoV-HKU1 (isolate N5) Spike Trimer, His Tag (MALS verified), 50µg

Background
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant HCoV-HKU1 (isolate N5) Spike Trimer, His Tag (SPN-H52H5) is the ectodomain of HCoV-HKU1 (isolate N5) spike protein which contains AA Ala 13 - Asn 1276 (Accession # Q0ZME7-1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. The S1/S2 furin-recognition site 752-RRKRR-756 is mutated to GGSGS to generate the uncleaved protein. Proline substitutions (N1067P, L1068P) are introduced to stabilize the trimeric prefusion state of the spike protein.
Predicted N-terminus: Ala 13

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 145.5 kDa. The protein migrates as 180-210 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial"
Chappell, Mordant, Amarilla et al
EBioMedicine (2023) 97, 104842
(2) "Quantitative analysis of residual aurintricarboxylic acid in biotherapeutic process streams using liquid chromatography triple quadrupole mass spectrometry"
Buckley, MacHale, Bones
J Pharm Biomed Anal (2023) 238, 115798
(3) "Inferring mechanical properties of the SARS-CoV-2 virus particle with nano-indentation tests and numerical simulations"
Nonn, Kiss, Pezeshkian et al
J Mech Behav Biomed Mater (2023) 148, 106153
Showing 1-3 of 34470 papers.